Chromatin Remodeling Governs Clinical Response to EZH2/EZH1 Inhibition

Skip Nav Destination

February 29, 2024

Major Finding: Clinical responses to the EZH1/2 inhibitor valemetostat are driven by the loosening of chromatin structure.

Concept: Increased accessibility induces expression of tumor suppressor genes, which were previously silenced.

Impact: These data suggest that reprogramming the cancer epigenome could lead to sustained clinical benefit.

DOI:https://doi.org/10.1158/2159-8290.CD-RW2024-036

Article Type: Research Watch

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Sign in